Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Formation of the Platelet Plug

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Clot Retraction and Fibrinolysis

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Artificial Intelligence in Vascular Neurology: Applications, Challenges, and a Review of AI Tools for Stroke Imaging, Clinical Decision Making, and Outcome Prediction Models.

Current neurology and neuroscience reports·2025

Same author

Global Impact of the COVID-19 Pandemic on Stroke Volumes and Cerebrovascular Events: A 1-Year Follow-up.

Neurology·2022

Same author

Global Impact of the COVID-19 Pandemic on Cerebral Venous Thrombosis and Mortality.

Journal of stroke·2022

Same author

Safety and Outcomes of Intravenous Thrombolytic Therapy in Ischemic Stroke Patients with COVID-19: CASCADE Initiative.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2021

Same author

Global Impact of COVID-19 on Stroke Care and IV Thrombolysis.

Neurology·2021

Same author

Neurologic complications of cardiac arrest.

Handbook of clinical neurology·2021

Search research articles

Related Experiment Video

Updated: May 9, 2026

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Platelet antiaggregants in stroke prevention.

Sarkis G Morales Vidal¹, Sean Ruland

¹Neurology Department, Stritch School of Medicine, Loyola University Chicago, 2160 South 1st Avenue, Building 105, Room 2700, Maywood, IL 60153, USA. smoralesvidal@lumc.edu

Neurologic Clinics

|July 31, 2013

Summary

Antiplatelet agents help prevent recurrent ischemic strokes. This review updates evidence on their optimal use, including timing, dosage, and combinations, for stroke risk reduction and managing side effects.

Keywords:

Antiplatelet Aspirin Cilostazol Clopidogrel Dypiridamole Hemorrhage Stroke

More Related Videos

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

Microfluidics in Assessing Platelet Function

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Related Experiment Videos

Last Updated: May 9, 2026

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

Microfluidics in Assessing Platelet Function

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Area of Science:

Neurology
Cardiology
Pharmacology

Background:

Antiplatelet therapy is crucial for preventing recurrent ischemic strokes.
The efficacy and safety of antiplatelet agents depend on various factors like timing, dosage, and combination therapies.

Purpose of the Study:

To provide an evidence-based update on the latest advancements in antiplatelet therapy for stroke prevention.
To analyze the impact of different antiplatelet strategies on stroke risk reduction and adverse events.

Main Methods:

Systematic review of recent clinical trials and observational studies.
Analysis of data concerning timing, dosage, and combination of antiplatelet agents.
Evaluation of reported stroke recurrence rates and bleeding complications.

Main Results:

Different antiplatelet regimens show varying degrees of effectiveness in reducing stroke recurrence.
Specific dosages and treatment durations are associated with distinct risk-benefit profiles.
Combination antiplatelet therapy may offer enhanced protection but increases bleeding risk.

Conclusions:

Optimizing antiplatelet therapy requires careful consideration of individual patient factors and therapeutic strategies.
Evidence-based guidelines are essential for guiding the appropriate use of antiplatelet agents in stroke prevention.
Further research is needed to refine antiplatelet protocols for maximizing efficacy and minimizing adverse effects.